BR112018075206A2 - tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida - Google Patents

tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida

Info

Publication number
BR112018075206A2
BR112018075206A2 BR112018075206-1A BR112018075206A BR112018075206A2 BR 112018075206 A2 BR112018075206 A2 BR 112018075206A2 BR 112018075206 A BR112018075206 A BR 112018075206A BR 112018075206 A2 BR112018075206 A2 BR 112018075206A2
Authority
BR
Brazil
Prior art keywords
difluoroacetamide
dioxopiperidin
oxoisoindolin
chlorophenyl
methyl
Prior art date
Application number
BR112018075206-1A
Other languages
English (en)
Inventor
CARRANCIO Soraya
Hollenbach Paul
Lopez-Girona Antonia
Macbeth Kyle
POURDEHNAD Michael
Rappley Irit
Lu Gang
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of BR112018075206A2 publication Critical patent/BR112018075206A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

são aqui fornecidos métodos de tratamento, prevenção, gestão e/ou melhoria de leucemia ou síndrome mielodisplásica compreendendo administrar 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida ou um estereoisômero ou uma mistura de estereoisômeros, um isotopólogo, sal, tautômero, solvato, hidrato, cocristal, clatrato ou polimorfo farmaceuticamente aceitável do mesmo a um paciente.
BR112018075206-1A 2016-06-06 2017-06-05 tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida BR112018075206A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346344P 2016-06-06 2016-06-06
US62/346,344 2016-06-06
PCT/US2017/035892 WO2017214014A1 (en) 2016-06-06 2017-06-05 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Publications (1)

Publication Number Publication Date
BR112018075206A2 true BR112018075206A2 (pt) 2019-03-19

Family

ID=60482040

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075206-1A BR112018075206A2 (pt) 2016-06-06 2017-06-05 tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida

Country Status (15)

Country Link
US (4) US10245258B2 (pt)
EP (1) EP3463358A4 (pt)
JP (1) JP7163281B2 (pt)
KR (1) KR20190015300A (pt)
CN (2) CN109414436A (pt)
AU (2) AU2017278114B2 (pt)
BR (1) BR112018075206A2 (pt)
CA (1) CA3026396A1 (pt)
CL (1) CL2018003499A1 (pt)
EA (1) EA201892746A1 (pt)
IL (1) IL262565B (pt)
MX (1) MX2018015120A (pt)
SG (1) SG11201809501PA (pt)
WO (1) WO2017214014A1 (pt)
ZA (1) ZA201807105B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
EP3399980A4 (en) * 2016-01-08 2019-09-04 Celgene Corporation METHODS OF TREATING CANCER AND USE OF BIOMARKERS AS FACTORS PREDICTIVE OF CLINICAL SENSITIVITY TO TREATMENTS
US11535603B1 (en) 2016-09-30 2022-12-27 Deuterx, Llc Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same
JP2022515670A (ja) * 2018-12-31 2022-02-21 セルジーン コーポレイション ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの組成物及び使用方法
PE20221155A1 (es) * 2019-11-05 2022-07-18 Celgene Corp Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
US11312699B2 (en) 2019-12-06 2022-04-26 Celgene Corporation Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CN115515582A (zh) * 2020-03-16 2022-12-23 细胞基因公司 急性髓系白血病的组合疗法
WO2022066835A1 (en) * 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469119A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20090175869A1 (en) 2007-05-31 2009-07-09 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
ATE505194T1 (de) 2009-05-20 2011-04-15 Hybrigenics Sa Neue therapeutische verwendungen von inecalcitol
US9125884B2 (en) 2011-11-01 2015-09-08 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
SG11201604504VA (en) * 2013-12-05 2016-07-28 Hoffmann La Roche Novel combination treatment for acute myeloid leukemia (aml)
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
JP7071922B2 (ja) 2016-01-08 2022-05-19 セルジーン コーポレイション ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの固体形態、ならびにそれらの薬学的組成物及び使用
CA3010797C (en) 2016-01-08 2024-01-02 Celgene Corporation Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
PL3399978T3 (pl) 2016-01-08 2021-04-06 Celgene Corporation Związki antyproliferacyjne oraz ich kompozycje farmaceutyczne i zastosowania

Also Published As

Publication number Publication date
EP3463358A1 (en) 2019-04-10
CA3026396A1 (en) 2017-12-14
US20230158009A1 (en) 2023-05-25
US20210154182A1 (en) 2021-05-27
IL262565B (en) 2022-08-01
US10245258B2 (en) 2019-04-02
JP7163281B2 (ja) 2022-10-31
CN109414436A (zh) 2019-03-01
MX2018015120A (es) 2019-04-15
EP3463358A4 (en) 2020-07-22
WO2017214014A1 (en) 2017-12-14
CN115282149A (zh) 2022-11-04
AU2023202159A1 (en) 2023-05-04
SG11201809501PA (en) 2018-12-28
US11590117B2 (en) 2023-02-28
KR20190015300A (ko) 2019-02-13
US20170348298A1 (en) 2017-12-07
EA201892746A1 (ru) 2019-06-28
JP2019517587A (ja) 2019-06-24
ZA201807105B (en) 2020-01-29
US20190175573A1 (en) 2019-06-13
CL2018003499A1 (es) 2019-03-15
AU2017278114A1 (en) 2018-11-29
IL262565A (en) 2018-12-31
AU2017278114B2 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
BR112018075206A2 (pt) tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
ECSP20013248A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
MX2019002212A (es) Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos.
ZA202202097B (en) Amino pyrimidine ssao inhibitors
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
ECSP18051143A (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
CL2019003857A1 (es) Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas.
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
EA201590345A1 (ru) Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
CY1121988T1 (el) Θεραπευτικη αγωγη της πολλαπλης σκληρυνσης
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
TR201906325T4 (tr) Tetrazolon sübstitüeli dihidropiridinon MGAT2 inhibitörleri.
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.
EA202193015A1 (ru) Ингибиторы cdk
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
BR112022018515A2 (pt) Terapia de combinação para leucemia mieloide aguda
MX2021007800A (es) Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
CO2022005861A2 (es) Terapia de combinación con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]